Immunosuppression, Influenza
Conditions
Keywords
Influenza, Solid Organ Transplant, Infection, Vaccine, Immunogenicity
Brief summary
The study will test whether a high dose influenza vaccination results in improved immunogenicity in adult SOT recipients as compared to standard vaccine. This will be a single center prospective observer-blind randomized controlled trial conducted at the Toronto General Hospital Multi-Organ Transplant Unit, University Health Network, Toronto, Ontario, Canada.
Detailed description
Influenza virus is an important cause of morbidity and mortality in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for transplant patients, studies have shown that standard vaccine has poor immunogenicity. Currently, there are no studies that define the effect of high-dose vaccine in adult transplant recipients even though this population could potentially benefit from it. The study will compare the immunogenicity of two different types of the influenza vaccine in 240 solid organ transplant patients during the 2016-2017 season. Patients will be randomized to receive either high-dose or standard dose influenza vaccine. Antibody titers will be evaluated by a standard hemagglutination inhibition assay. The hypothesis is that the patients who receive the high-dose influenza vaccine will reach a significantly greater response to the vaccine. This study advances research on the prevention of serious viral infections in transplant recipients. Results from this study have the potential to directly improve patient care. If the use of the high-dose influenza vaccine is successful, this strategy may lead to significant reduction in burden of disease, hospitalization, and long-term morbidity.
Interventions
BIOLOGICALFluzone High-dose Influenza Vaccine
This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
BIOLOGICALStandard 2016-2017 Flu vaccine
The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
Sponsors
University Health Network, Toronto
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Organ transplant recipient on at least one immunosuppressive * Age \>=18 * Outpatient status * Greater than 3 months post transplant
Exclusion criteria
* Has already received influenza vaccination for 2016-2017 season * Egg allergy or allergy to previous influenza vaccine * Febrile illness in the past one week * Active Cytomegalovirus viremia * Use of Rituximab in the past 6 months * Ongoing or recent (in past 30 days) therapy for acute rejection * Chronic kidney insufficiency (creatinine clearance ≤30mL/min or dialysis-dependent * Previous life-threatening reaction to influenza vaccine (i.e. Guillain Barre Syndrome) * Receipt of intravenous immunoglobulin (IVIG) in the past 30 days or planning to receive IVIG in the next 4 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vaccine Immunogenicity (antibody titers) | 4 weeks | Comparing pre-vaccine and 4 weeks Post-Vaccine antibody titers. Positive vaccine response will be defined as: * Seroconversion rate of 4-fold or greater increase in HAI antibody titers to each of the three antigens in the vaccine, and * seroprotection rate determined by HAI tigers of 1\>=40 post immunization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vaccine Safety (local and systemic adverse events to vaccination). | 6 months | Vaccine Safety assessed by local and systemic adverse events to vaccination. |
| Vaccine Safety (rates of rejection). | 6 months | Vaccine Safety assessed by rates of biopsy proven allograft rejection in the 6 months following vaccination. |
| Vaccine Immunogenicity (CMI) | 4 weeks | Analysis of cell-mediated immunity (CMI) in subgroup of 50 patients at 4 weeks post-vaccination vs pre-vaccination samples. CMI response will be correlated with HAI response. |
| Vaccine Efficacy (influenza infection) | 6 months | Microbiology proven influenza infection in the 6 months following vaccination. |
Countries
Canada
Outcome results
None listed